260 related articles for article (PubMed ID: 33081832)
1. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
2. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
3. Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients.
Miller BF; Petrykowska HM; Elnitski L
Sci Rep; 2021 Jan; 11(1):221. PubMed ID: 33420235
[TBL] [Abstract][Full Text] [Related]
4. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
5. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
6. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
7. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.
Buckley DN; Lewinger JP; Gooden G; Spillman M; Neuman M; Guo XM; Tew BY; Miller H; Khetan VU; Shulman LP; Roman L; Salhia B
Clin Cancer Res; 2023 Dec; 29(24):5196-5206. PubMed ID: 37812492
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation marker to estimate ovarian cancer cell fraction.
Ebata T; Yamashita S; Takeshima H; Yoshida H; Kawata Y; Kino N; Yasugi T; Terao Y; Yonemori K; Kato T; Ushijima T
Med Oncol; 2022 Feb; 39(5):78. PubMed ID: 35195779
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.
Li L; Zheng H; Huang Y; Huang C; Zhang S; Tian J; Li P; Sood AK; Zhang W; Chen K
Carcinogenesis; 2017 Aug; 38(8):797-805. PubMed ID: 28637314
[TBL] [Abstract][Full Text] [Related]
10. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.
Sánchez-Vega F; Gotea V; Petrykowska HM; Margolin G; Krivak TC; DeLoia JA; Bell DW; Elnitski L
Epigenetics; 2013 Dec; 8(12):1355-72. PubMed ID: 24149212
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
Zeng H; He B; Yi C; Peng J
J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
[TBL] [Abstract][Full Text] [Related]
12. Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development.
Margolin G; Petrykowska HM; Jameel N; Bell DW; Young AC; Elnitski L
J Mol Diagn; 2016 Mar; 18(2):283-98. PubMed ID: 26857064
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation biomarkers discovered
Vrba L; Oshiro MM; Kim SS; Garland LL; Placencia C; Mahadevan D; Nelson MA; Futscher BW
Epigenetics; 2020 Apr; 15(4):419-430. PubMed ID: 31775567
[TBL] [Abstract][Full Text] [Related]
14. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.
Yang Y; Wu L; Shu X; Lu Y; Shu XO; Cai Q; Beeghly-Fadiel A; Li B; Ye F; Berchuck A; Anton-Culver H; Banerjee S; Benitez J; Bjørge L; Brenton JD; Butzow R; Campbell IG; Chang-Claude J; Chen K; Cook LS; Cramer DW; deFazio A; Dennis J; Doherty JA; Dörk T; Eccles DM; Edwards DV; Fasching PA; Fortner RT; Gayther SA; Giles GG; Glasspool RM; Goode EL; Goodman MT; Gronwald J; Harris HR; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Kar SP; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Koushik A; Lambrechts D; Le ND; Levine DA; Massuger LF; Matsuo K; May T; McNeish IA; Menon U; Modugno F; Monteiro AN; Moorman PG; Moysich KB; Ness RB; Nevanlinna H; Olsson H; Onland-Moret NC; Park SK; Paul J; Pearce CL; Pejovic T; Phelan CM; Pike MC; Ramus SJ; Riboli E; Rodriguez-Antona C; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Shan K; Siddiqui N; Sieh W; Stampfer MJ; Sutphen R; Swerdlow AJ; Szafron LM; Teo SH; Tworoger SS; Tyrer JP; Webb PM; Wentzensen N; White E; Willett WC; Wolk A; Woo YL; Wu AH; Yan L; Yannoukakos D; Chenevix-Trench G; Sellers TA; Pharoah PDP; Zheng W; Long J
Cancer Res; 2019 Feb; 79(3):505-517. PubMed ID: 30559148
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing.
Zhang H; Dong P; Guo S; Tao C; Chen W; Zhao W; Wang J; Cheung R; Villanueva A; Fan J; Ding H; Schrodi SJ; Zhang D; Zeng C
BMC Med; 2020 Aug; 18(1):200. PubMed ID: 32741373
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
Herzog C; Jones A; Evans I; Reisel D; Olaitan A; Doufekas K; MacDonald N; Rådestad AF; Gemzell-Danielsson K; Zikan M; Cibula D; Dostálek L; Paprotka T; Leimbach A; Schmitt M; Ryan A; Gentry-Maharaj A; Apostolidou S; Rosenthal AN; Menon U; Widschwendter M
Int J Cancer; 2024 Feb; 154(4):679-691. PubMed ID: 37861205
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
[TBL] [Abstract][Full Text] [Related]
18. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
